



Overview

Endonovo Therapeutics, Inc. (OTCQB: ENDV) is a biotechnology company developing off-the-shelf regenerative products that no longer require the injection of stem cells. Our first platform, Cell Free Therapeutics, harnesses the biological secretions of cells to create therapies that can be immediately administered following injuries or to treat acute and chronic diseases. Our second platform is the development of non-invasive, bioelectronics to stimulate the body's natural repair system to treat injuries and inflammatory diseases.

Management Team

Alan Collier

Chairman & Chief Executive Officer

Garry Michael Kann

Head of Corporate Development

Recent News

Monday, December 04, 2023 - 09:15 AM

[Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of \\$50 Million](#)

Thursday, October 12, 2023 - 09:07 AM

[Endonovo's SofPulse® Secures Taiwan FDA Approval](#)

Tuesday, August 22, 2023 - 09:07 AM

[Endonovo's SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution](#)

Tuesday, August 08, 2023 - 09:03 AM

[Endonovo's Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update](#)

Wednesday, June 07, 2023 - 09:07 AM

[Endonovo Pending Agreement to Develop Telehealth Division](#)

DISCLAIMER


Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other

Contact Information

Endonovo Therapeutics, Inc.

6320 Canoga Ave
15th Floor
Woodland Hills, CA 91367

OTCQB: ENDV



| | |
|--------------------|-------------|
| Share Price | \$0.01 |
| Volume | 54k |
| Shares Outstanding | 318,751,597 |
| Market Cap | \$2.71m |
| 52 Week High | \$0.02 |
| 52 Week Low | \$0.01 |

as of 01/16/2024

risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.